Physician profile
Mallory Cranmer
NPI 1831500933
$3,601.05
in general payments reported to CMS, 2019-2025
22 companies · $743 in 2025
The $743 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $172 · 2021: $186 · 2022: $509 · 2023: $893 · 2024: $891 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,277 · Entertainment: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,277.37 |
| Entertainment | $249.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $391.60 | 2021-2025 | Cequa |
| Bausch & Lomb Americas INC. | $354.73 | 2022-2025 | Miebo, Infuse, Xiidra |
| Alcon Vision LLC | $334.70 | 2019-2025 | Dailies Total1, Precision 1, Total30 |
| Coopervision INC. | $268.02 | 2023-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Optos, INC. | $249.69 | 2023-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Dompe US, INC. | $234.84 | 2023-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $230.21 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $226.66 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $191.99 | 2020-2024 | |
| Sight Sciences, INC. | $166.95 | 2022 | |
| Biotissue Holdings INC. | $152.67 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $150.98 | 2021-2023 | |
| Harrow Eye, LLC | $134.23 | 2024-2025 | Vevye |
| Lkc Technologies, INC. | $117.34 | 2023 | |
| Oyster Point Pharma, INC. | $117.25 | 2022-2025 | Tyrvaya, Ryzumvi |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $78.39 | 2022 | |
| Abbvie INC. | $72.50 | 2023-2024 | Lumigan, Vuity |
| Kala Pharmaceuticals, INC. | $43.36 | 2021-2022 | |
| Allergan, INC. | $35.18 | 2020-2022 | |
| Abb Con-Cise Optical Group LLC | $29.55 | 2025 | Contact Lens |
| Eyevance Pharmaceuticals LLC | $20.21 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Cranmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.